The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Novel evidence‐based systemic lupus erythematosus responder index
Open accessAbstract
Objective: To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. Methods: Data from a randomized, double‐blind, placebo‐controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56‐week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti–double‐stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. Results: SRI response is defined as 1) a ≥4‐point reduction in SELENA–SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by ≥0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype. Conclusion: This evidence‐based evaluation of a large randomized, placebo‐controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Self-citation(2016) · Diagnostic Imaging: Brain · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Self-citationOverview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605
Gladman, D., Ginzler, E., Goldsmith, C., Fortin, P., Liang, M., Sanchez‐Guerrero, J., Urowitz, M., Bacon, P., Bombardieri, S., Hanly, J., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390303 · Cited by 2,582
Self-citationRahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Cited by
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912196 · Cited by 1,379
Self-citationWallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M. A., Dörner, T., Cardiel, M. H., Bruce, I. N., Gomez, E., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31363-1 · Cited by 513
Self-citationLai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30485-9 · Cited by 412
Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
Rai, S. K., Yazdany, J., Fortin, P. R., & Aviña-Zubieta, J. A. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0658-6 · Cited by 251
Clowse, M. E. B., Wallace, D. J., Furie, R. A., Petri, M. A., Pike, M. C., Leszczyński, P., Neuwelt, C. M., Hobbs, K., Keiserman, M., Duca, L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39856 · Cited by 235
Self-citation
Metadata
- Authors
- Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., Zhong, Z. J., & Freimuth, W. W.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2009-08-27
- Volume
- 61
- Issue
- 9
- Pages
- 1143-1151
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W2091468965
- Cited by
- 490
- References
- 45
- FWCI
- 21.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel evidence‐based systemic lupus erythematosus responder index. https://app.cochat.ai/papers/10.1002/art.24698
- The paper
- Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., Zhong, Z. J., & Freimuth, W. W. (2009). Novel evidence‐based systemic lupus erythematosus responder index. Arthritis Care & Research. https://doi.org/10.1002/art.24698
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
